Y
Yosef S. Haviv
Researcher at Hebrew University of Jerusalem
Publications - 82
Citations - 1532
Yosef S. Haviv is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Kidney disease & Kidney. The author has an hindex of 21, co-authored 76 publications receiving 1449 citations. Previous affiliations of Yosef S. Haviv include University of Alabama at Birmingham & Hadassah Medical Center.
Papers
More filters
Journal ArticleDOI
Blockade of Transforming Growth Factor-β1 Accelerates Lymphatic Regeneration during Wound Repair
Tomer Avraham,Sanjay V. Daluvoy,Jaime Zampell,Alan Yan,Yosef S. Haviv,Stanley G. Rockson,Babak J. Mehrara +6 more
TL;DR: Inhibition of TGF-β function promoted lymphatic regeneration, decreased tissue fibrosis, decreased chronic inflammation and Th2 cell migration, and improved lymphatic function, and the use of these strategies may represent a novel means of preventing lymphedema after lymph node resection.
Journal ArticleDOI
The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography
Meir Gare,Yosef S. Haviv,Arie Ben-Yehuda,Dvorah Rubinger,Tali Bdolah-Abram,Shmuel Fuchs,Ora Gat,Mordecai M. Popovtzer,Mervyn S. Gotsman,Morris Mosseri +9 more
TL;DR: There is no advantage of dopamine over adequate hydration in patients with mild to moderate renal failure or DM undergoing coronary angiography, and Dopamine should be avoided in Patients with PVD exposed to contrast medium.
Journal ArticleDOI
The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.
Winan J. van Houdt,Yosef S. Haviv,Baogen Lu,Minghui Wang,Angel A. Rivera,Ilya V. Ulasov,Martine L.M. Lamfers,Daniel T. Rein,Maciej S. Lesniak,Gene P. Siegal,Clemens M F Dirven,David T. Curiel,Zeng B. Zhu +12 more
TL;DR: Data indicate that the survivin promoter is a promising tumor-specific promoter for transcriptional targeting of adenovirus-based vectors and CRAds for malignant gliomas, and the strategy of using survivin-CRAds may translate into an experimental therapeutic approach that can be used in human clinical trials.
Journal ArticleDOI
Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition
TL;DR: Whether adipose-derived stem cells can be used in lymphatic tissue-engineering by altering the balance between pro- and anti-lymphangiogenic cytokines is determined and short-term stimulation of ASCs with VEGF-C results in increased expression of V EGF-A, VEGf-C and Prox-1 in vitro and is associated with a marked increase lymphangiogenesis response after in vivo implantation.
Journal ArticleDOI
Conditional gene targeting for cancer gene therapy.
Yosef S. Haviv,David T. Curiel +1 more
TL;DR: Novel approaches for conditional gene expression in cancer cells are discussed and the regulation of both replication and transgene expression by conditionally-replicative viruses are discussed to increase the therapeutic index of future vectors for cancer gene therapy.